Alternating anti-prion regimens reduce combination drug resistance but do not further extend survival in scrapie-infected mice

J Gen Virol. 2021 Dec;102(12):001705. doi: 10.1099/jgv.0.001705.

Abstract

Prion diseases are fatal and infectious neurodegenerative diseases in humans and other mammals caused by templated misfolding of the endogenous prion protein (PrP). Although there is currently no vaccine or therapy against prion disease, several classes of small-molecule compounds have been shown to increase disease-free incubation time in prion-infected mice. An apparent obstacle to effective anti-prion therapy is the emergence of drug-resistant strains during static therapy with either single compounds or multi-drug combination regimens. Here, we treated scrapie-infected mice with dynamic regimens that alternate between different classes of anti-prion drugs. The results show that alternating regimens containing various combinations of Anle138b, IND24 and IND116135 reduce the incidence of combination drug resistance, but do not significantly increase long-term disease-free survival compared to monotherapy. Furthermore, the alternating regimens induced regional vacuolation profiles resembling those generated by a single component of the alternating regimen, suggesting the emergence of strain dominance.

Keywords: Anle138b; drug; prion; scrapie; therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Brain / pathology
  • Disease Models, Animal
  • Disease-Free Survival
  • Drug Resistance / drug effects*
  • Drug Therapy, Combination
  • Infectious Disease Incubation Period
  • Mice
  • Prions / antagonists & inhibitors*
  • Prions / drug effects
  • Scrapie / drug therapy*
  • Scrapie / mortality
  • Scrapie / pathology

Substances

  • Prions